Cargando…
A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts
INTRODUCTION: Traditional methods of screening plant extracts and purified components for antiviral activity require up to a week to perform, prompting the need to develop more rapid quantitative methods to measure the ability of plant based preparations to block viral replication. We describe an ad...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications Pvt Ltd
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141131/ https://www.ncbi.nlm.nih.gov/pubmed/21808571 http://dx.doi.org/10.4103/0974-8490.69108 |
_version_ | 1782208631815536640 |
---|---|
author | Cock, Ian Kalt, F. R. |
author_facet | Cock, Ian Kalt, F. R. |
author_sort | Cock, Ian |
collection | PubMed |
description | INTRODUCTION: Traditional methods of screening plant extracts and purified components for antiviral activity require up to a week to perform, prompting the need to develop more rapid quantitative methods to measure the ability of plant based preparations to block viral replication. We describe an adaption of an MS2 plaque reduction assay for use in S. aureus. RESULTS: MS2 bacteriophage was capable of infecting and replicating in B. cereus, S. aureus and F + E. coli but not F- E. coli. Indeed, both B. cereus and S. aureus were more sensitive to MS2 induced lysis than F+ E. coli. When MS2 bacteriophage was mixed with Camellia sinensis extract (1 mg/ml), Scaevola spinescens extract (1 mg/ml) or Aloe barbadensis juice and the mixtures inoculated into S. aureus, the formation of plaques was reduced to 8.9 ± 3.8%, 5.4 ± 2.4% and 72.7 ± 20.9% of the untreated MS2 control values respectively. CONCLUSIONS: The ability of the MS2 plaque reduction assay to detect antiviral activity in these known antiviral plant preparations indicates its suitability as an antiviral screening tool. An advantage of this assay compared with traditionally used cytopathic effect reduction assays and replicon based assays is the more rapid acquisition of results. Antiviral activity was detected within 24 h of the start of testing. The MS2 assay is also inexpensive and non-pathogenic to humans making it ideal for initial screening studies or as a simulant for pathogenic viruses. |
format | Online Article Text |
id | pubmed-3141131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Medknow Publications Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31411312011-08-01 A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts Cock, Ian Kalt, F. R. Pharmacognosy Res Original Article INTRODUCTION: Traditional methods of screening plant extracts and purified components for antiviral activity require up to a week to perform, prompting the need to develop more rapid quantitative methods to measure the ability of plant based preparations to block viral replication. We describe an adaption of an MS2 plaque reduction assay for use in S. aureus. RESULTS: MS2 bacteriophage was capable of infecting and replicating in B. cereus, S. aureus and F + E. coli but not F- E. coli. Indeed, both B. cereus and S. aureus were more sensitive to MS2 induced lysis than F+ E. coli. When MS2 bacteriophage was mixed with Camellia sinensis extract (1 mg/ml), Scaevola spinescens extract (1 mg/ml) or Aloe barbadensis juice and the mixtures inoculated into S. aureus, the formation of plaques was reduced to 8.9 ± 3.8%, 5.4 ± 2.4% and 72.7 ± 20.9% of the untreated MS2 control values respectively. CONCLUSIONS: The ability of the MS2 plaque reduction assay to detect antiviral activity in these known antiviral plant preparations indicates its suitability as an antiviral screening tool. An advantage of this assay compared with traditionally used cytopathic effect reduction assays and replicon based assays is the more rapid acquisition of results. Antiviral activity was detected within 24 h of the start of testing. The MS2 assay is also inexpensive and non-pathogenic to humans making it ideal for initial screening studies or as a simulant for pathogenic viruses. Medknow Publications Pvt Ltd 2010 /pmc/articles/PMC3141131/ /pubmed/21808571 http://dx.doi.org/10.4103/0974-8490.69108 Text en Copyright: © Pharmacognosy Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Cock, Ian Kalt, F. R. A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title | A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title_full | A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title_fullStr | A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title_full_unstemmed | A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title_short | A modified MS2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
title_sort | modified ms2 bacteriophage plaque reduction assay for the rapid screening of antiviral plant extracts |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141131/ https://www.ncbi.nlm.nih.gov/pubmed/21808571 http://dx.doi.org/10.4103/0974-8490.69108 |
work_keys_str_mv | AT cockian amodifiedms2bacteriophageplaquereductionassayfortherapidscreeningofantiviralplantextracts AT kaltfr amodifiedms2bacteriophageplaquereductionassayfortherapidscreeningofantiviralplantextracts AT cockian modifiedms2bacteriophageplaquereductionassayfortherapidscreeningofantiviralplantextracts AT kaltfr modifiedms2bacteriophageplaquereductionassayfortherapidscreeningofantiviralplantextracts |